论文部分内容阅读
目的 探讨不同耐药模式的耐药因子对膀胱癌化疗耐药形成的影响。方法 应用免疫组织化学技术检测 44例膀胱移行上皮癌和 6例正常膀胱粘膜标本中谷胱甘肽S 转移酶 π(GST π)和多药耐药相关蛋白 (MRP)表达 ,并用计算机图像分析技术进行半定量分析。结果 44例膀胱移行上皮癌GST π、MRP表达的阳性率分别为 72 .7%和 6 8.2 % ,明显高于在正常粘膜的表达 (16 .7%、33 .3 % ,P >0 .0 5 ) ;GST π的表达有随肿瘤分级、分期升高的趋势 ,化疗后复发病例亦高于初发病例 ,但差异无显著性 (P <0 .0 5 ) ;MRP的表达与肿瘤的分级、分期及其化疗与否并无明显相关 ;两者的表达显示有明显的相关性 (r =0 .6 85 ,P <0 .0 0 1)。结论 GST π和MRP两者表达的相关性提示其表达可能存在共同的调节机制 ,从而使之在膀胱癌化疗耐药的形成过程中发挥关键作用
Objective To investigate the resistance of different drug resistance patterns of bladder cancer chemoresistance formation. Methods The expression of GST π and multidrug resistance-associated protein (MRP) in 44 cases of transitional cell carcinoma of the bladder and 6 cases of normal bladder mucosa were detected by immunohistochemistry and analyzed by computer image analysis Semi-quantitative analysis. Results The positive rates of GST π and MRP in 44 cases of bladder transitional cell carcinoma were 72.7% and 62.2%, respectively, which were significantly higher than those in normal mucosa (16.7%, 33.3%, P> 0. 0) 5). The expression of GST π tended to increase with tumor grade and stage. The recurrence rate after chemotherapy was also higher than that of the initial cases, but the difference was not statistically significant (P0.05). The expression of MRP was correlated with the tumor grade There was no significant correlation between staging and chemotherapy. The two groups showed significant correlation (r = 0.855, P <0.001). Conclusion The correlation between the expression of GST π and MRP suggests that there may be a common regulatory mechanism in the expression of GST π and MRP, which may play a key role in the formation of chemoresistance in bladder cancer